Barbosa Marcus Vinícius Jardini, Nahas Fabio Xerfan, Ferreira Lydia Masako, Farah Andréia Bufoni, Bariani Roberta Lopes, João Benedito Barbosa
São Paulo, SP / Brazil.
Aesthetic Plast Surg. 2004 Jan-Feb;28(1):33-6. doi: 10.1007/s00266-004-3087-5. Epub 2004 Apr 2.
Ondansetron has been used widely in plastic surgery to prevent postoperative nausea and vomiting. A literature search showed controversial dosages of this drug, and because of its short half-life, its use only before anesthetic induction could have a limited effect. The purpose of this study was to assess the efficacy of intravenous (IV) ondansetron (4 mg) for aesthetic plastic surgery performed with the patient under general anesthesia and the prophylaxis of postoperative nausea and vomiting (PONV) in two situations: (a) only before anesthetic induction and (b) before anesthetic induction and immediately before extubation.
Of the 60 patients who had general anesthesia for aesthetic plastic surgery, 30 received 4 mg of IV ondansetron before anesthetic induction (control group) and 30 received 4 mg of IV ondansetron before anesthetic induction plus 4 mg IV immediately before extubation (experimental group). The PONV was recorded in the postanesthetic care unit and in the hospital room.
The total occurrence of PONV (n = 60) was 6.7%. In the postanesthetic care unit, one patient in the experimental group (3.3%) manifested this symptom. In the hospital room, two patients in the control group (6.7%) and one patient in the experimental group (3.3%) manifested PONV.
According to the findings, there was no statistical difference between the groups. However, the dosage used in the control group was effective and less expensive.
昂丹司琼已广泛应用于整形外科手术中以预防术后恶心和呕吐。一项文献检索显示该药物的剂量存在争议,并且由于其半衰期短,仅在麻醉诱导前使用可能效果有限。本研究的目的是评估静脉注射(IV)昂丹司琼(4毫克)对在全身麻醉下接受美容整形手术患者的疗效,以及在两种情况下预防术后恶心和呕吐(PONV)的效果:(a)仅在麻醉诱导前使用;(b)在麻醉诱导前和拔管前即刻使用。
在60例接受美容整形手术全身麻醉的患者中,30例在麻醉诱导前接受4毫克IV昂丹司琼(对照组),30例在麻醉诱导前接受4毫克IV昂丹司琼并在拔管前即刻追加4毫克IV(实验组)。在麻醉后护理单元和病房记录PONV情况。
PONV的总发生率(n = 60)为6.7%。在麻醉后护理单元,实验组有1例患者(3.3%)出现该症状。在病房,对照组有2例患者(6.7%)和实验组有1例患者(3.3%)出现PONV。
根据研究结果,两组之间无统计学差异。然而,对照组使用的剂量是有效的且成本更低。